Using Phenotyping to Guide Treatment in Group 2 Pulmonary Hypertension: Are We Out of the Woods Yet?

This session will explore the evolving landscape of Group 2 pulmonary hypertension, beginning with key updates from the 7th World Symposium and a review of phenotypes and hemodynamic classifications. The discussion will continue with emerging data on the impact of SGLT2 inhibitors on right heart structure and function, current literature on pulmonary vasodilator therapies, and considerations for optimal patient selection.

Agenda

• Moderator - Thomas Cascino, MD, FHFSA
• Moderator - Jessica Huston, MD
• Updates in Group 2 PH Evaluation and Classification from the 7th WSPH - TBD
• Medical Therapies in Group 2 PH and Right Heart Failure - Aaron Bagnola, PharmD
• Panel Discussion